{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:55Z","timestamp":1793814055628,"version":"4.6.1"},"reference-count":358,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41573-026-01388-5","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:52:04Z","timestamp":1774878724000},"page":"469-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A renaissance in targeting the PI3K\/AKT\/mTOR pathway"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5075-8851","authenticated-orcid":false,"given":"Sarah E.","family":"Conduit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-484X","authenticated-orcid":false,"given":"Neil","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-0746","authenticated-orcid":false,"given":"Matthew W. D.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7074-3673","authenticated-orcid":false,"given":"Bart","family":"Vanhaesebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1388_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"1388_CR2","first-page":"1667","volume":"63","author":"C Sawyer","year":"2003","unstructured":"Sawyer, C. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110\u03b4. Cancer Res. 63, 1667\u20131675 (2003).","journal-title":"Cancer Res."},{"key":"1388_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1042\/CS20190772","volume":"134","author":"L Xenou","year":"2020","unstructured":"Xenou, L. & Papakonstanti, E. A. p110\u03b4 PI3K as a therapeutic target of solid tumours. Clin. Sci. 134, 1377\u20131397 (2020).","journal-title":"Clin. Sci."},{"key":"1388_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","volume":"19","author":"N Vasan","year":"2022","unstructured":"Vasan, N. & Cantley, L. C. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat. Rev. Clin. Oncol. 19, 471\u2013485 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1388_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel, P., Toska, E., Engelman, J. A. & Scaltriti, M. The present and future of PI3K inhibitors for cancer therapy. Nat. Cancer 2, 587\u2013597 (2021).","journal-title":"Nat. Cancer"},{"key":"1388_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"B Vanhaesebroeck","year":"2021","unstructured":"Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., Andre, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug. Discov. 20, 741\u2013769 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1388_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605\u2013635 (2017).","journal-title":"Cell"},{"key":"1388_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat. Rev. Drug. Discov. 4, 988\u20131004 (2005).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1388_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395\u2013402 (2007).","journal-title":"Cancer Cell"},{"key":"1388_CR10","doi-asserted-by":"publisher","first-page":"15259","DOI":"10.1073\/pnas.1205508109","volume":"109","author":"JE Burke","year":"2012","unstructured":"Burke, J. E., Perisic, O., Masson, G. R., Vadas, O. & Williams, R. L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110\u03b1 (PIK3CA). Proc. Natl Acad. Sci. USA 109, 15259\u201315264 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR11","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1073\/pnas.1617244114","volume":"114","author":"GL Dornan","year":"2017","unstructured":"Dornan, G. L. et al. Conformational disruption of PI3K\u03b4 regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc. Natl Acad. Sci. USA 114, 1982\u20131987 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR12","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1016\/j.jaip.2021.07.044","volume":"9","author":"J Oh","year":"2021","unstructured":"Oh, J., Garabedian, E., Fuleihan, R. & Cunningham-Rundles, C. Clinical manifestations and outcomes of activated phosphoinositide 3-kinase \u03b4 syndrome from the USIDNET cohort. J. Allergy Clin. Immunol. Pract. 9, 4095\u20134102 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1388_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","volume":"30","author":"S Singh","year":"2024","unstructured":"Singh, S. et al. FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin. Cancer Res. 30, 23\u201328 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-genom-121222-114518","volume":"25","author":"GM Morin","year":"2024","unstructured":"Morin, G. M. et al. PIK3CA-related disorders: from disease mechanism to evidence-based treatments. Annu. Rev. Genomics Hum. Genet. 25, 211\u2013237 (2024).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"1388_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MOH.0000000000000496","volume":"26","author":"SD Castillo","year":"2019","unstructured":"Castillo, S. D., Baselga, E. & Graupera, M. PIK3CA mutations in vascular malformations. Curr. Opin. Hematol. 26, 170\u2013178 (2019).","journal-title":"Curr. Opin. Hematol."},{"key":"1388_CR16","doi-asserted-by":"publisher","first-page":"110400","DOI":"10.1016\/j.clim.2024.110400","volume":"270","author":"VK Rao","year":"2025","unstructured":"Rao, V. K. et al. A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase \u03b4 (PI3K\u03b4) syndrome (APDS): adolescent and adult subgroup analysis. Clin. Immunol. 270, 110400 (2025).","journal-title":"Clin. Immunol."},{"key":"1388_CR17","first-page":"171","volume":"346","author":"C Costa","year":"2010","unstructured":"Costa, C. & Hirsch, E. More than just kinases: the scaffolding function of PI3K. Curr. Top. Microbiol. Immunol. 346, 171\u2013181 (2010).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1388_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","volume":"30","author":"B Vanhaesebroeck","year":"2005","unstructured":"Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194\u2013204 (2005).","journal-title":"Trends Biochem. Sci."},{"key":"1388_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1749-6632.2009.05081.x","volume":"1188","author":"F Damilano","year":"2010","unstructured":"Damilano, F., Perino, A. & Hirsch, E. PI3K kinase and scaffold functions in heart. Ann. N. Y. Acad. Sci. 1188, 39\u201345 (2010).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1388_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2004.07.018","volume":"118","author":"B Vanhaesebroeck","year":"2004","unstructured":"Vanhaesebroeck, B., Rohn, J. L. & Waterfield, M. D. Gene targeting: attention to detail. Cell 118, 274\u2013276 (2004).","journal-title":"Cell"},{"key":"1388_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00018-025-05937-w","volume":"82","author":"SE Conduit","year":"2025","unstructured":"Conduit, S. E. et al. Novel role for PI3K\u03b2 in placental function through regulation of system A amino acid transporter expression, associated with embryonic lethality. Cell Mol. Life Sci. 82, 413 (2025).","journal-title":"Cell Mol. Life Sci."},{"key":"1388_CR22","first-page":"169","volume":"13","author":"L Bi","year":"2002","unstructured":"Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110\u03b2 catalytic subunit of PI3-kinase. Mamm. Genome 13, 169\u2013172 (2002).","journal-title":"Mamm. Genome"},{"key":"1388_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005304","volume":"11","author":"J Guillermet-Guibert","year":"2015","unstructured":"Guillermet-Guibert, J. et al. Novel role for p110\u03b2 PI3-kinase in male fertility through regulation of androgen receptor activity in Sertoli cells. PLoS Genet. 11, e1005304 (2015).","journal-title":"PLoS Genet."},{"key":"1388_CR24","doi-asserted-by":"publisher","first-page":"ra3","DOI":"10.1126\/scisignal.1161577","volume":"1","author":"E Ciraolo","year":"2008","unstructured":"Ciraolo, E. et al. Phosphoinositide 3-kinase p110\u03b2 activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).","journal-title":"Sci. Signal."},{"key":"1388_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2004.07.017","volume":"118","author":"E Patrucco","year":"2004","unstructured":"Patrucco, E. et al. PI3K\u03b3 modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375\u2013387 (2004).","journal-title":"Cell"},{"key":"1388_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 20, 515\u2013534 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1388_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41580-022-00490-x","volume":"23","author":"Y Posor","year":"2022","unstructured":"Posor, Y., Jang, W. & Haucke, V. Phosphoinositides as membrane organizers. Nat. Rev. Mol. Cell Biol. 23, 797\u2013816 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1388_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tips.2023.06.002","volume":"44","author":"D Cirillo","year":"2023","unstructured":"Cirillo, D., Diceglie, M. & Nazare, M. Isoform-selective targeting of PI3K: time to consider new opportunities? Trends Pharmacol. Sci. 44, 601\u2013621 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"1388_CR29","doi-asserted-by":"publisher","first-page":"14278","DOI":"10.1021\/acs.jmedchem.3c01319","volume":"66","author":"M Kucukdisli","year":"2023","unstructured":"Kucukdisli, M. et al. Structural basis for highly selective class II \u03b1 phosphoinositide-3-kinase inhibition. J. Med. Chem. 66, 14278\u201314302 (2023).","journal-title":"J. Med. Chem."},{"key":"1388_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41589-022-01118-z","volume":"19","author":"WT Lo","year":"2023","unstructured":"Lo, W. T. et al. Development of selective inhibitors of phosphatidylinositol 3-kinase C2\u03b1. Nat. Chem. Biol. 19, 18\u201327 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1388_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/ncb3053","volume":"16","author":"WE Dowdle","year":"2014","unstructured":"Dowdle, W. E. et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 16, 1069\u20131079 (2014).","journal-title":"Nat. Cell Biol."},{"key":"1388_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/nchembio.1681","volume":"10","author":"B Ronan","year":"2014","unstructured":"Ronan, B. et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat. Chem. Biol. 10, 1013\u20131019 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"1388_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/BJ20140889","volume":"463","author":"R Bago","year":"2014","unstructured":"Bago, R. et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem. J. 463, 413\u2013427 (2014).","journal-title":"Biochem. J."},{"key":"1388_CR34","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1021\/acs.jmedchem.1c01180","volume":"65","author":"DX Hu","year":"2022","unstructured":"Hu, D. X. et al. Structure-based design of potent, selective, and orally bioavailable VPS34 kinase inhibitors. J. Med. Chem. 65, 11500\u201311512 (2022).","journal-title":"J. Med. Chem."},{"key":"1388_CR35","doi-asserted-by":"publisher","first-page":"eaar8430","DOI":"10.1126\/scitranslmed.aar8430","volume":"12","author":"MV Selvadurai","year":"2020","unstructured":"Selvadurai, M. V. et al. Disrupting the platelet internal membrane via PI3KC2\u03b1 inhibition impairs thrombosis independently of canonical platelet activation. Sci. Transl. Med. 12, eaar8430 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1388_CR36","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051299","volume":"22","author":"T Anquetil","year":"2021","unstructured":"Anquetil, T. et al. PI3KC2\u03b2 inactivation stabilizes VE-cadherin junctions and preserves vascular integrity. EMBO Rep. 22, e51299 (2021).","journal-title":"EMBO Rep."},{"key":"1388_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1021\/acs.jmedchem.9b01585","volume":"63","author":"ZA Henley","year":"2020","unstructured":"Henley, Z. A. et al. Optimization of orally bioavailable PI3K\u03b4 inhibitors and identification of Vps34 as a key selectivity target. J. Med. Chem. 63, 638\u2013655 (2020).","journal-title":"J. Med. Chem."},{"key":"1388_CR38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2533\/chimia.2021.1037","volume":"75","author":"C Borsari","year":"2021","unstructured":"Borsari, C. & Wymann, M. P. Targeting phosphoinositide 3-kinase\u2014five decades of chemical space exploration. Chimia 75, 1037\u20131044 (2021).","journal-title":"Chimia"},{"key":"1388_CR39","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","volume":"23","author":"J Mateo","year":"2017","unstructured":"Mateo, J. et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase \u03b2-selective inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5981\u20135992 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","volume":"12","author":"BC O\u2019Connell","year":"2024","unstructured":"O\u2019Connell, B. C. et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J. Immunother. Cancer 12, e009160 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1388_CR41","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin. Cancer Res. 29, 2210\u20132219 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR42","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.1016\/j.bmcl.2012.08.102","volume":"22","author":"F Giordanetto","year":"2012","unstructured":"Giordanetto, F. et al. Discovery of phosphoinositide 3-kinases (PI3K) p110\u03b2 isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyri midin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. Bioorg Med. Chem. Lett. 22, 6671\u20136676 (2012).","journal-title":"Bioorg Med. Chem. Lett."},{"key":"1388_CR43","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","volume":"10","author":"S Nylander","year":"2012","unstructured":"Nylander, S. et al. Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor. J. Thromb. Haemost. 10, 2127\u20132136 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"1388_CR44","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.13027","volume":"13","author":"S Nylander","year":"2015","unstructured":"Nylander, S., Wagberg, F., Andersson, M., Skarby, T. & Gustafsson, D. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man. J. Thromb. Haemost. 13, 1494\u20131502 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"1388_CR45","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR46","doi-asserted-by":"publisher","first-page":"283ra251","DOI":"10.1126\/scitranslmed.aaa4442","volume":"7","author":"A Bosch","year":"2015","unstructured":"Bosch, A. et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl. Med. 7, 283ra251 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1388_CR47","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aah6893","volume":"355","author":"E Toska","year":"2017","unstructured":"Toska, E. et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355, 1324\u20131330 (2017).","journal-title":"Science"},{"key":"1388_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-025-00752-9","volume":"11","author":"V Cutano","year":"2025","unstructured":"Cutano, V. et al. The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA\/PTEN altered estrogen receptor positive breast cancer. npj Breast Cancer 11, 36 (2025).","journal-title":"npj Breast Cancer"},{"key":"1388_CR49","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo, H. S. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet. Oncol. 25, e629\u2013e638 (2024).","journal-title":"Lancet. Oncol."},{"key":"1388_CR50","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR51","unstructured":"Genentech. Genentech\u2019s itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer. Gene.com https:\/\/www.gene.com\/media\/press-releases\/15049\/2025-01-27\/genentechs-itovebi-demonstrated-statisti (2025)."},{"key":"1388_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri, K. L. et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2501796 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR53","doi-asserted-by":"publisher","first-page":"TPS1123","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1123","volume":"41","author":"D Juric","year":"2023","unstructured":"Juric, D. et al. INAVO121: phase III study of inavolisib (INAVO)\u2009+\u2009fulvestrant (FUL) vs. alpelisib (ALP)\u2009+\u2009 FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2\u2013) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA\/mBC). J. Clin. Oncol. 41, TPS1123 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1388_CR54","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1182\/blood-2024-198497","volume":"144","author":"G Canaud","year":"2024","unstructured":"Canaud, G. et al. Epik-P2: a phase 2 study of alpelisib (ALP) in pediatric and adult patients (pts) with PIK3CA-related overgrowth spectrum (PROS). Blood 144, 5512 (2024).","journal-title":"Blood"},{"key":"1388_CR55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2174\/1568026620666200224101808","volume":"20","author":"NE Uko","year":"2020","unstructured":"Uko, N. E., Guner, O. F., Matesic, D. F. & Bowen, J. P. Akt pathway inhibitors. Curr. Top. Med. Chem. 20, 883\u2013900 (2020).","journal-title":"Curr. Top. Med. Chem."},{"key":"1388_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13543776.2023.2273895","volume":"33","author":"L Li","year":"2023","unstructured":"Li, L. et al. An updated patent review of AKT inhibitors (2020\u2013present). Expert. Opin. Ther. Pat. 33, 549\u2013564 (2023).","journal-title":"Expert. Opin. Ther. Pat."},{"key":"1388_CR57","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.004","author":"K Fizazi","year":"2025","unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004 (2025).","journal-title":"Ann. Oncol."},{"key":"1388_CR59","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","volume":"30","author":"SS Skanland","year":"2024","unstructured":"Skanland, S. S., Okkenhaug, K. & Davids, M. S. PI3K inhibitors in hematology: when one door closes. Clin. Cancer Res. 30, 3667\u20133675 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288114","author":"P Ghione","year":"2025","unstructured":"Ghione, P., Zinzani, P. L. & Brown, J. R. Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Haematologica https:\/\/doi.org\/10.3324\/haematol.2025.288114 (2025).","journal-title":"Haematologica"},{"key":"1388_CR61","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann, C. U. & Wiestner, A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin. Cancer Biol. 23, 410\u2013421 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"1388_CR62","first-page":"123","volume":"393","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug, K. & Burger, J. A. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Curr. Top. Microbiol. Immunol. 393, 123\u2013142 (2016).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1388_CR63","doi-asserted-by":"publisher","first-page":"uxae107","DOI":"10.1093\/cei\/uxae107","volume":"219","author":"J Whalen","year":"2025","unstructured":"Whalen, J. et al. Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase \u03b4 (PI3K\u03b4) syndrome (APDS): an externally controlled study. Clin. Exp. Immunol. 219, uxae107 (2025).","journal-title":"Clin. Exp. Immunol."},{"key":"1388_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114498","volume":"238","author":"P Oleksak","year":"2022","unstructured":"Oleksak, P. et al. Contemporary mTOR inhibitor scaffolds to diseases breakdown: a patent review (2015\u20132021). Eur. J. Med. Chem. 238, 114498 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1388_CR65","first-page":"CD011272","volume":"7","author":"TH Sasongko","year":"2016","unstructured":"Sasongko, T. H., Ismail, N. F. & Zabidi-Hussin, Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst. Rev. 7, CD011272 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1388_CR66","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery, S. E. & Mayer, I. A. Management of toxicity to isoform \u03b1-specific PI3K inhibitors. Ann. Oncol. 30, x21\u2013x26 (2019).","journal-title":"Ann. Oncol."},{"key":"1388_CR67","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature04694","volume":"441","author":"LC Foukas","year":"2006","unstructured":"Foukas, L. C. et al. Critical role for the p110\u03b1 phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366\u2013370 (2006).","journal-title":"Nature"},{"key":"1388_CR68","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2353\/ajpath.2010.090931","volume":"176","author":"L He","year":"2010","unstructured":"He, L. et al. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am. J. Pathol. 176, 2302\u20132308 (2010).","journal-title":"Am. J. Pathol."},{"key":"1388_CR69","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","volume":"2020","author":"A Hanlon","year":"2020","unstructured":"Hanlon, A. & Brander, D. M. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol. Am. Soc. Hematol Educ. Program. 2020, 346\u2013356 (2020).","journal-title":"Hematol. Am. Soc. Hematol Educ. Program."},{"key":"1388_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1078-0432.CCR-14-3239","volume":"22","author":"AM Eiden","year":"2016","unstructured":"Eiden, A. M., Zhang, S., Gary, J. M., Simmons, J. K. & Mock, B. A. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Clin. Cancer Res. 22, 277\u2013283 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR71","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","volume":"287","author":"T Sasaki","year":"2000","unstructured":"Sasaki, T. et al. Function of PI3K\u03b3a in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040\u20131046 (2000).","journal-title":"Science"},{"key":"1388_CR72","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"K Okkenhaug","year":"2002","unstructured":"Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110\u03b4 PI3-kinase mutant mice. Science 297, 1031\u20131034 (2002).","journal-title":"Science"},{"key":"1388_CR73","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1182\/blood-2010-05-287821","volume":"117","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117, 1228\u20131238 (2011).","journal-title":"Blood"},{"key":"1388_CR74","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo, H. S. et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet. Oncol. 18, 654\u2013662 (2017).","journal-title":"Lancet. Oncol."},{"key":"1388_CR75","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70069","volume":"55","author":"EL Lim","year":"2025","unstructured":"Lim, E. L., Qian, Y., Sugihara, F., Tanaka, A. & Sakaguchi, S. Loss of PI3K\u03b4 activity drives autoimmune colitis by impairing extrathymic Treg differentiation. Eur. J. Immunol. 55, e70069 (2025).","journal-title":"Eur. J. Immunol."},{"key":"1388_CR77","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","volume":"605","author":"S Eschweiler","year":"2022","unstructured":"Eschweiler, S. et al. Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs. Nature 605, 741\u2013746 (2022).","journal-title":"Nature"},{"key":"1388_CR78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson, B. L. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128, 195\u2013203 (2016).","journal-title":"Blood"},{"key":"1388_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.016","author":"S Ma","year":"2020","unstructured":"Ma, S. et al. Retrospective analysis of the impact of adverse event-triggered idelalisib interruption and dose reduction on clinical outcomes in patients with relapsed\/refractory B-cell malignancies. Clin. Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2020.12.016 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1388_CR80","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1080\/10428194.2021.1948038","volume":"62","author":"ND Wagner-Johnston","year":"2021","unstructured":"Wagner-Johnston, N. D. et al. Idelalisib immune-related toxicity is associated with improved treatment response. Leuk. Lymphoma 62, 2915\u20132920 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"1388_CR81","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2007-04-086751","volume":"110","author":"H Ji","year":"2007","unstructured":"Ji, H. et al. Inactivation of PI3K\u03b3 and PI3K\u03b4 distorts T-cell development and causes multiple organ inflammation. Blood 110, 2940\u20132947 (2007).","journal-title":"Blood"},{"key":"1388_CR82","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/psp4.12749","volume":"11","author":"K Gadkar","year":"2022","unstructured":"Gadkar, K. et al. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors. CPT Pharmacomet. Syst. Pharmacol. 11, 616\u2013627 (2022).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1388_CR83","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"1388_CR84","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nbt.3882","volume":"35","author":"M Hafner","year":"2017","unstructured":"Hafner, M., Niepel, M. & Sorger, P. K. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat. Biotechnol. 35, 500\u2013502 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1388_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.166","volume":"4","author":"M Hafner","year":"2017","unstructured":"Hafner, M. et al. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci. Data 4, 170166 (2017).","journal-title":"Sci. Data"},{"key":"1388_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01383-w","volume":"8","author":"M Niepel","year":"2017","unstructured":"Niepel, M. et al. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat. Commun. 8, 1186 (2017).","journal-title":"Nat. Commun."},{"key":"1388_CR87","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1158\/1078-0432.CCR-23-2540","volume":"30","author":"U Grazini","year":"2024","unstructured":"Grazini, U. et al. Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA\/PTEN alterations. Clin. Cancer Res. 30, 4143\u20134154 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14683","volume":"8","author":"T Bohnacker","year":"2017","unstructured":"Bohnacker, T. et al. Deconvolution of Buparlisib\u2019s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nat. Commun. 8, 14683 (2017).","journal-title":"Nat. Commun."},{"key":"1388_CR89","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies, B. R. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11, 873\u2013887 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.24523","volume":"6","author":"Y Zwang","year":"2017","unstructured":"Zwang, Y. et al. Synergistic interactions with PI3K inhibition that induce apoptosis. eLife 6, e24523 (2017).","journal-title":"eLife"},{"key":"1388_CR91","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","volume":"24","author":"C Tarantelli","year":"2018","unstructured":"Tarantelli, C. et al. PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy. Clin. Cancer Res. 24, 120\u2013129 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00648-0","volume":"10","author":"S Rossetti","year":"2024","unstructured":"Rossetti, S. et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K\/AKT\/mTOR inhibitors in breast cancer models. NPJ Breast Cancer 10, 40 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"1388_CR93","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.3390\/cancers16203520","volume":"16","author":"A Broege","year":"2024","unstructured":"Broege, A. et al. Functional assessments of gynecologic cancer models highlight differences between single-node inhibitors of the PI3K\/AKT\/mTOR pathway and a pan-PI3K\/mTOR inhibitor, gedatolisib. Cancers 16, 3520 (2024).","journal-title":"Cancers"},{"key":"1388_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.06.017","volume":"340","author":"SY Sun","year":"2013","unstructured":"Sun, S. Y. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 340, 1\u20138 (2013).","journal-title":"Cancer Lett."},{"key":"1388_CR95","doi-asserted-by":"publisher","first-page":"20274","DOI":"10.1039\/D4SC05459H","volume":"15","author":"L Bissegger","year":"2024","unstructured":"Bissegger, L. et al. Rapid, potent, and persistent covalent chemical probes to deconvolute PI3K\u03b1 signaling. Chem. Sci. 15, 20274\u201320291 (2024).","journal-title":"Chem. Sci."},{"key":"1388_CR96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/0008-5472.CAN-24-0529","volume":"85","author":"V Ramponi","year":"2025","unstructured":"Ramponi, V. et al. H4K20me3-mediated repression of inflammatory genes is a characteristic and targetable vulnerability of persister cancer cells. Cancer Res. 85, 32\u201351 (2025).","journal-title":"Cancer Res."},{"key":"1388_CR97","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/382536a0","volume":"382","author":"JZ Morris","year":"1996","unstructured":"Morris, J. Z., Tissenbaum, H. A. & Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382, 536\u2013539 (1996).","journal-title":"Nature"},{"key":"1388_CR98","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477\u20132488 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ccell.2014.11.007","volume":"27","author":"C Costa","year":"2015","unstructured":"Costa, C. et al. Measurement of PIP3 levels reveals an unexpected role for p110\u03b2 in early adaptive responses to p110\u03b1-specific inhibitors in luminal breast cancer. Cancer Cell 27, 97\u2013108 (2015).","journal-title":"Cancer Cell"},{"key":"1388_CR100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","volume":"27","author":"S Schwartz","year":"2015","unstructured":"Schwartz, S. et al. Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2. Cancer Cell 27, 109\u2013122 (2015).","journal-title":"Cancer Cell"},{"key":"1388_CR101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58\u201371 (2011).","journal-title":"Cancer Cell"},{"key":"1388_CR102","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2010.626","volume":"30","author":"V Serra","year":"2011","unstructured":"Serra, V. et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547\u20132557 (2011).","journal-title":"Oncogene"},{"key":"1388_CR103","doi-asserted-by":"publisher","first-page":"101170","DOI":"10.1016\/j.drup.2024.101170","volume":"78","author":"X Niu","year":"2025","unstructured":"Niu, X. et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug. Resist. Updat. 78, 101170 (2025).","journal-title":"Drug. Resist. Updat."},{"key":"1388_CR104","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath, J., Gammoh, N. & Ryan, K. M. Autophagy and autophagy-related pathways in cancer. Nat. Rev. Mol. Cell Biol. 24, 560\u2013575 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1388_CR105","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature 518, 240\u2013244 (2015).","journal-title":"Nature"},{"key":"1388_CR106","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-16-0305","volume":"6","author":"X Le","year":"2016","unstructured":"Le, X. et al. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov. 6, 1134\u20131147 (2016).","journal-title":"Cancer Discov."},{"key":"1388_CR107","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali, K. et al. Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407\u2013411 (2014).","journal-title":"Nature"},{"key":"1388_CR108","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.18053","volume":"197","author":"D Gadi","year":"2022","unstructured":"Gadi, D. et al. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. Br. J. Haematol. 197, 207\u2013211 (2022).","journal-title":"Br. J. Haematol."},{"key":"1388_CR109","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.V122.21.678.678","volume":"122","author":"MC Lanasa","year":"2013","unstructured":"Lanasa, M. C. et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3K\u03b4, in adult patients with relapsed or refractory lymphoid malignancies. Blood 122, 678\u2013678 (2013).","journal-title":"Blood"},{"key":"1388_CR110","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","volume":"6","author":"LS Carnevalli","year":"2018","unstructured":"Carnevalli, L. S. et al. PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. J. Immunother. Cancer 6, 158 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1388_CR111","doi-asserted-by":"publisher","unstructured":"Maio, M. et al. Tolerability and clinical benefit assessment of continuous roginolisib administration in patients with cancer including metastatic uveal melanoma. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-8048398\/v1 (2025).","DOI":"10.21203\/rs.3.rs-8048398\/v1"},{"key":"1388_CR112","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/nature02991","volume":"431","author":"K Ali","year":"2004","unstructured":"Ali, K. et al. Essential role for the p110\u03b4 phosphoinositide 3-kinase in the allergic response. Nature 431, 1007\u20131011 (2004).","journal-title":"Nature"},{"key":"1388_CR113","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.4049\/jimmunol.180.4.2538","volume":"180","author":"K Ali","year":"2008","unstructured":"Ali, K. et al. Isoform-specific functions of phosphoinositide 3-kinases: p110\u03b4 but not p110\u03b3 promotes optimal allergic responses in vivo. J. Immunol. 180, 2538\u20132544 (2008).","journal-title":"J. Immunol."},{"key":"1388_CR114","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.4049\/jimmunol.2000326","volume":"205","author":"N Diaz","year":"2020","unstructured":"Diaz, N. et al. Seletalisib for activated PI3K\u03b4 syndromes: open-label phase 1b and extension studies. J. Immunol. 205, 2979\u20132987 (2020).","journal-title":"J. Immunol."},{"key":"1388_CR115","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/bloodadvances.2023011620","volume":"8","author":"A Yacoub","year":"2024","unstructured":"Yacoub, A. et al. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 8, 1515\u20131528 (2024).","journal-title":"Blood Adv."},{"key":"1388_CR116","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.chemrestox.8b00023","volume":"31","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Identification of novel pathways in idelalisib metabolism and bioactivation. Chem. Res. Toxicol. 31, 548\u2013555 (2018).","journal-title":"Chem. Res. Toxicol."},{"key":"1388_CR117","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-015-2891-8","volume":"77","author":"F Jin","year":"2016","unstructured":"Jin, F. et al. Population pharmacokinetic modeling of idelalisib, a novel PI3K\u03b4 inhibitor, in healthy subjects and patients with hematologic malignancies. Cancer Chemother. Pharmacol. 77, 89\u201398 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1388_CR118","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1158\/2767-9764.CRC-22-0477","volume":"3","author":"Z Johnson","year":"2023","unstructured":"Johnson, Z. et al. IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K\u03b4 inhibitor that targets solid tumors and breaks immune tolerance. Cancer Res. Commun. 3, 576\u2013591 (2023).","journal-title":"Cancer Res. Commun."},{"key":"1388_CR119","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/10915818231200419","volume":"42","author":"L van der Veen","year":"2023","unstructured":"van der Veen, L., Schmitt, M., Deken, M. A. & Lahn, M. Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase \u03b4 inhibitor roginolisib. Int. J. Toxicol. 42, 515\u2013534 (2023).","journal-title":"Int. J. Toxicol."},{"key":"1388_CR120","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao, V. K. et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood 141, 971\u2013983 (2023).","journal-title":"Blood"},{"key":"1388_CR121","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","volume":"153","author":"VK Rao","year":"2024","unstructured":"Rao, V. K. et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J. Allergy Clin. Immunol. 153, 265\u2013274 e269 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1388_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00300-X","volume":"23","author":"JR Brown","year":"2022","unstructured":"Brown, J. R., Danilov, A. V., LaCasce, A. S. & Davids, M. S. PI3K inhibitors in haematological malignancies. Lancet. Oncol. 23, e364 (2022).","journal-title":"Lancet. Oncol."},{"key":"1388_CR123","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.eclinm.2024.102520","volume":"71","author":"A Llombart-Cussac","year":"2024","unstructured":"Llombart-Cussac, A. et al. Preventing alpelisib-related hyperglycaemia in HR+\/HER2\u2013\/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine 71, 102520 (2024).","journal-title":"EClinicalMedicine"},{"key":"1388_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00613-x","volume":"10","author":"EJ Gallagher","year":"2024","unstructured":"Gallagher, E. J. et al. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer 10, 12 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"1388_CR125","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920967259","volume":"12","author":"PF Peddi","year":"2020","unstructured":"Peddi, P. F. et al. Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. Ther. Adv. Med. Oncol. 12, 1758835920967259 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1388_CR126","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah, C. Y. & Fowler, N. H. Idelalisib in the management of lymphoma. Blood 128, 331\u2013336 (2016).","journal-title":"Blood"},{"key":"1388_CR127","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood.2019001795","volume":"134","author":"K Patel","year":"2019","unstructured":"Patel, K., Danilov, A. V. & Pagel, J. M. Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma. Blood 134, 1573\u20131577 (2019).","journal-title":"Blood"},{"key":"1388_CR128","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40262-021-01066-2","volume":"61","author":"NA Miller","year":"2022","unstructured":"Miller, N. A. et al. Physiologically based pharmacokinetic modelling of inhaled nemiralisib: mechanistic components for pulmonary absorption, systemic distribution, and oral absorption. Clin. Pharmacokinet. 61, 281\u2013293 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"1388_CR129","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1021\/acs.jmedchem.4c02062","volume":"68","author":"P Bruno","year":"2025","unstructured":"Bruno, P. et al. Discovery of CHF-6523, an inhaled selective PI3K\u03b4 inhibitor for the treatment of chronic obstructive pulmonary disease. J. Med. Chem. 68, 2444\u20132465 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR130","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12931-024-02999-5","volume":"25","author":"M Govoni","year":"2024","unstructured":"Govoni, M. et al. CHF6523 data suggest that the phosphoinositide 3-kinase \u03b4 isoform is not a suitable target for the management of COPD. Respir. Res. 25, 380 (2024).","journal-title":"Respir. Res."},{"key":"1388_CR131","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1021\/acs.jmedchem.1c00434","volume":"64","author":"MWD Perry","year":"2021","unstructured":"Perry, M. W. D. et al. Discovery of AZD8154, a dual PI3K\u03b3\u03b4 inhibitor for the treatment of asthma. J. Med. Chem. 64, 8053\u20138075 (2021).","journal-title":"J. Med. Chem."},{"key":"1388_CR132","unstructured":"Torqur. Bimiralisib, topical PI3K\/mTOR inhibitor shows up to 92% clearance rate and superior tolerability in proof-of-concept actinic keratosis study. swissrockets https:\/\/swissrockets.com\/news\/bimiralisib-topical-pi3k-mtor-inhibitor-shows-up-to-92-perents-clearance-rate-and-superior-tolerability-in-proof-of-concept-actinic-keratosis-study (2025)."},{"key":"1388_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07698-6","volume":"9","author":"CC Campa","year":"2018","unstructured":"Campa, C. C. et al. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat. Commun. 9, 5232 (2018).","journal-title":"Nat. Commun."},{"key":"1388_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14292","volume":"8","author":"A Mizrachi","year":"2017","unstructured":"Mizrachi, A. et al. Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nat. Commun. 8, 14292 (2017).","journal-title":"Nat. Commun."},{"key":"1388_CR135","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric, D. et al. Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J. Clin. Oncol. 36, 1291\u20131299 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1388_CR136","unstructured":"US Food and Drug Administration. Itovebi (prescribing information). FDA.gov https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/219249s000lbl.pdf (2024)."},{"key":"1388_CR137","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A. et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann. Oncol. 27, 1928\u20131940 (2016).","journal-title":"Ann. Oncol."},{"key":"1388_CR138","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12","author":"N Liu","year":"2013","unstructured":"Liu, N. et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12, 2319\u20132330 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.138","volume":"8","author":"AD Zelenetz","year":"2024","unstructured":"Zelenetz, A. D. et al. The PI3K\u03b4 inhibitor zandelisib on intermittent dosing in relapsed\/refractory follicular lymphoma: results from a global phase 2 study. Hemasphere 8, e138 (2024).","journal-title":"Hemasphere"},{"key":"1388_CR140","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(24)00034-2","volume":"25","author":"RM Layman","year":"2024","unstructured":"Layman, R. M. et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet. Oncol. 25, 474\u2013487 (2024).","journal-title":"Lancet. Oncol."},{"key":"1388_CR141","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-19-3953","volume":"26","author":"LM Smyth","year":"2020","unstructured":"Smyth, L. M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer. Clin. Cancer Res. 26, 3947\u20133957 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR142","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131\u2013142 (2021).","journal-title":"Lancet"},{"key":"1388_CR143","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3431","author":"CK McCourt","year":"2025","unstructured":"McCourt, C. K. et al. Ipatasertib in patients with tumors with AKT mutations: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) sub-protocol Z1K. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3431 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR144","doi-asserted-by":"publisher","first-page":"LBA1005","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005","volume":"43","author":"SKL Chia","year":"2025","unstructured":"Chia, S. K. L. et al. A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitor: the CCTG\/BCT MA.40\/FINER study (NCT04650581). J. Clin. Oncol. 43, LBA1005 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1388_CR145","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3390\/ijms24032289","volume":"24","author":"F Raith","year":"2023","unstructured":"Raith, F., O\u2019Donovan, D. H., Lemos, C., Politz, O. & Haendler, B. Addressing the reciprocal crosstalk between the AR and the PI3K\/AKT\/mTOR signaling pathways for prostate cancer treatment. Int. J. Mol. Sci. 24, 2289 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1388_CR146","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575\u2013586 (2011).","journal-title":"Cancer Cell"},{"key":"1388_CR147","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/ijms24032046","volume":"24","author":"E Tortorella","year":"2023","unstructured":"Tortorella, E., Giantulli, S., Sciarra, A. & Silvestri, I. AR and PI3K\/AKT in prostate cancer: a tale of two interconnected pathways. Int. J. Mol. Sci. 24, 2046 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1388_CR148","unstructured":"AstraZeneca. Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 phase III trial. AstraZeneca.com https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/truqap-improved-rpfs-in-advanced-prostate-cancer.html (2024)."},{"key":"1388_CR149","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.ejca.2024.114103","volume":"205","author":"P Rescigno","year":"2024","unstructured":"Rescigno, P. et al. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial. Eur. J. Cancer 205, 114103 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1388_CR150","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","volume":"39","author":"SJ Crabb","year":"2021","unstructured":"Crabb, S. J. et al. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). J. Clin. Oncol. 39, 190\u2013201 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1388_CR151","unstructured":"AstraZeneca. Update on CAPItello-280 phase III trial of truqap in metastatic castration-resistant prostate cancer. AstraZeneca.com https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-capitello-280-phase-iii-trial.html (2025)."},{"key":"1388_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.012","author":"PS Schmid","year":"2025","unstructured":"Schmid, P. S. et al. Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.012 (2025).","journal-title":"Ann. Oncol."},{"key":"1388_CR153","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","volume":"635","author":"AE Schade","year":"2024","unstructured":"Schade, A. E. et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature 635, 755\u2013763 (2024).","journal-title":"Nature"},{"key":"1388_CR154","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1158\/1535-7163.MCT-17-0024","volume":"16","author":"TT Vo","year":"2017","unstructured":"Vo, T. T. et al. mTORC1 inhibition induces resistance to methotrexate and 6-mercaptopurine in Ph+ and Ph-like B-ALL. Mol. Cancer Ther. 16, 1942\u20131953 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34890-6","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y. mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Nat. Commun. 13, 7047 (2022).","journal-title":"Nat. Commun."},{"key":"1388_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03035-z","author":"PA Tyrakis","year":"2025","unstructured":"Tyrakis, P. A. et al. Multi-node inhibition targeting mTORC1, mTORC2 and PI3K\u03b1 potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models. Br. J. Cancer https:\/\/doi.org\/10.1038\/s41416-025-03035-z (2025).","journal-title":"Br. J. Cancer"},{"key":"1388_CR157","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ygyno.2022.07.005","volume":"166","author":"DC Starks","year":"2022","unstructured":"Starks, D. C., Rojas-Espaillat, L., Meissner, T. & Williams, C. B. Phase I dose escalation study of dual PI3K\/mTOR inhibition by sapanisertib and serabelisib in combination with paclitaxel in patients with advanced solid tumors. Gynecol. Oncol. 166, 403\u2013409 (2022).","journal-title":"Gynecol. Oncol."},{"key":"1388_CR158","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins, B. D. et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560, 499\u2013503 (2018).","journal-title":"Nature"},{"key":"1388_CR159","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/neuonc\/noad117","volume":"25","author":"EK Noch","year":"2023","unstructured":"Noch, E. K. et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro Oncol. 25, 2165\u20132176 (2023).","journal-title":"Neuro Oncol."},{"key":"1388_CR160","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1016\/j.cell.2025.04.041","volume":"188","author":"A Roichman","year":"2025","unstructured":"Roichman, A. et al. Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors. Cell 188, 3065\u20133080.e21 (2025).","journal-title":"Cell"},{"key":"1388_CR161","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","volume":"23","author":"NC Richardson","year":"2022","unstructured":"Richardson, N. C., Kasamon, Y., Pazdur, R. & Gormley, N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet. Oncol. 23, 563\u2013566 (2022).","journal-title":"Lancet. Oncol."},{"key":"1388_CR162","first-page":"2974","volume":"110","author":"B Kandathilparambil Sasi","year":"2025","unstructured":"Kandathilparambil Sasi, B. et al. Novel PI3K\u03b4 inhibitor roginolisib synergizes with venetoclax in hematologic malignancies. Haematologica 110, 2974\u20132985 (2025).","journal-title":"Haematologica"},{"key":"1388_CR163","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1158\/1538-7445.AM2022-6240","volume":"82","author":"X Qin","year":"2022","unstructured":"Qin, X. et al. Abstract 6240: a phase 1 study of selective PI3K\u03b3 inhibitor ZX-4081 in patients with advanced solid tumors. Cancer Res. 82, 62400 (2022).","journal-title":"Cancer Res."},{"key":"1388_CR164","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"1388_CR165","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"1388_CR166","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu, H. et al. PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood 143, 1965\u20131979 (2024).","journal-title":"Blood"},{"key":"1388_CR167","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","volume":"630","author":"Q Luo","year":"2024","unstructured":"Luo, Q. et al. Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling. Nature 630, 198\u2013205 (2024).","journal-title":"Nature"},{"key":"1388_CR168","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s43018-024-00782-5","volume":"5","author":"LM Kelly","year":"2024","unstructured":"Kelly, L. M. et al. Targeting a lineage-specific PI3K\u03b3\u2013Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. Nat. Cancer 5, 1082\u20131101 (2024).","journal-title":"Nat. Cancer"},{"key":"1388_CR169","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027376","author":"Q Luo","year":"2025","unstructured":"Luo, Q., Fortune, A. L. & Lane, A. A. PI3K\u03b3 in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target. Blood https:\/\/doi.org\/10.1182\/blood.2024027376 (2025).","journal-title":"Blood"},{"key":"1388_CR170","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.chembiol.2024.06.009","volume":"31","author":"H Karvonen","year":"2024","unstructured":"Karvonen, H. & Vasan, N. Therapeutic potential of inhibiting the PI3K\u03b3 complex for leukemia. Cell Chem. Biol. 31, 1244\u20131246 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1388_CR171","doi-asserted-by":"publisher","first-page":"eabl6328","DOI":"10.1126\/scitranslmed.abl6328","volume":"14","author":"A Ghigo","year":"2022","unstructured":"Ghigo, A. et al. A PI3K\u03b3 mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. Sci. Transl. Med. 14, eabl6328 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1388_CR172","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"1388_CR173","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","volume":"617","author":"JS Bergholz","year":"2023","unstructured":"Bergholz, J. S. et al. PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours. Nature 617, 139\u2013146 (2023).","journal-title":"Nature"},{"key":"1388_CR174","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10147-024-02657-2","volume":"30","author":"J Li","year":"2025","unstructured":"Li, J. et al. Phase Ib study of the oral PI3K\u03b4 inhibitor linperlisib in patients with advanced solid tumors. Int. J. Clin. Oncol. 30, 241\u2013251 (2025).","journal-title":"Int. J. Clin. Oncol."},{"key":"1388_CR175","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03740-1","volume":"20","author":"L Mantoan Ritter","year":"2025","unstructured":"Mantoan Ritter, L. et al. mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node. Orphanet J. Rare Dis. 20, 256 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1388_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100969","volume":"25","author":"G Canaud","year":"2023","unstructured":"Canaud, G. et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet. Med. 25, 100969 (2023).","journal-title":"Genet. Med."},{"key":"1388_CR177","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/08880018.2025.2498660","volume":"42","author":"A Etingin","year":"2025","unstructured":"Etingin, A. et al. Alpelisib in pediatric PIK3CA- and TIE-2-mutant vascular anomalies: a case series on safety, efficacy, and drug exposure. Pediatr. Hematol. Oncol. 42, 228\u2013241 (2025).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"1388_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01745-0","volume":"16","author":"K Forde","year":"2021","unstructured":"Forde, K. et al. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. Orphanet J. Rare Dis. 16, 109 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1388_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03831-z","volume":"20","author":"W Eng","year":"2025","unstructured":"Eng, W. et al. Safety findings from the phase 1\/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome. Orphanet J. Rare Dis. 20, 375 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1388_CR180","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s44161-022-00107-8","volume":"1","author":"A Angulo-Urarte","year":"2022","unstructured":"Angulo-Urarte, A. & Graupera, M. When, where and which PIK3CA mutations are pathogenic in congenital disorders. Nat. Cardiovasc. Res. 1, 700\u2013714 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1388_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1446046","volume":"11","author":"G Kane","year":"2024","unstructured":"Kane, G. & Fernandez-Pineda, I. Targeted therapies for vascular malformations. Front. Med. 11, 1446046 (2024).","journal-title":"Front. Med."},{"key":"1388_CR182","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa2504411","volume":"393","author":"H Al-Samkari","year":"2025","unstructured":"Al-Samkari, H. et al. Engasertib versus placebo for bleeding in hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 393, 2131\u20132141 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1388_CR183","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1172\/JCI121277","volume":"129","author":"L Yehia","year":"2019","unstructured":"Yehia, L., Ngeow, J. & Eng, C. PTEN-opathies: from biological insights to evidence-based precision medicine. J. Clin. Invest. 129, 452\u2013464 (2019).","journal-title":"J. Clin. Invest."},{"key":"1388_CR184","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajhg.2013.05.019","volume":"93","author":"C Thauvin-Robinet","year":"2013","unstructured":"Thauvin-Robinet, C. et al. Mutations cause syndromic insulin resistance with lipoatrophy. Am. J. Hum. Genet. 93, 141\u2013149 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"1388_CR185","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/ng.2331","volume":"44","author":"JB Riviere","year":"2012","unstructured":"Riviere, J. B. et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 44, 934\u2013940 (2012).","journal-title":"Nat. Genet."},{"key":"1388_CR186","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nm.3824","volume":"21","author":"JS Lim","year":"2015","unstructured":"Lim, J. S. et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat. Med. 21, 395\u2013400 (2015).","journal-title":"Nat. Med."},{"key":"1388_CR187","doi-asserted-by":"publisher","unstructured":"Hummer, G. et al. PI3K\u03b4 is selectively inhibited by roginolisib through stabilizing of the C-terminal helix k\u03b112. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-8048396\/v1 (2025).","DOI":"10.21203\/rs.3.rs-8048396\/v1"},{"key":"1388_CR188","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","volume":"290","author":"JR Somoza","year":"2015","unstructured":"Somoza, J. R. et al. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase \u03b4. J. Biol. Chem. 290, 8439\u20138446 (2015).","journal-title":"J. Biol. Chem."},{"key":"1388_CR189","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nchembio.293","volume":"6","author":"A Berndt","year":"2010","unstructured":"Berndt, A. et al. The p110\u03b4 structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol. 6, 117\u2013124 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"1388_CR190","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0072","author":"KW Song","year":"2021","unstructured":"Song, K. W. et al. RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (inavolisib) efficacy. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0072 (2021).","journal-title":"Cancer Discov."},{"key":"1388_CR191","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-21-1411","volume":"12","author":"B Vanhaesebroeck","year":"2022","unstructured":"Vanhaesebroeck, B., Burke, J. E. & Madsen, R. R. Precision targeting of mutant PI3K\u03b1 in cancer by selective degradation. Cancer Discov. 12, 20\u201322 (2022).","journal-title":"Cancer Discov."},{"key":"1388_CR192","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","volume":"13","author":"L Buckbinder","year":"2023","unstructured":"Buckbinder, L. et al. STX-478, a mutant-selective, allosteric PI3K\u03b1 inhibitor spares metabolic dysfunction and improves therapeutic response in PI3K\u03b1-mutant xenografts. Cancer Discov. 13, 2432\u20132447 (2023).","journal-title":"Cancer Discov."},{"key":"1388_CR193","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/bj20031410","volume":"376","author":"I Rubio","year":"2003","unstructured":"Rubio, I., Rennert, K., Wittig, U. & Wetzker, R. Ras activation in response to lysophosphatidic acid requires a permissive input from the epidermal growth factor receptor. Biochem. J. 376, 571\u2013576 (2003).","journal-title":"Biochem. J."},{"key":"1388_CR194","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs22-p4-08-02","author":"L Puca","year":"2023","unstructured":"Puca, L. et al. Abstract P4-08-02: LOXO-783: a potent, highly mutant selective and brain-penetrant allosteric PI3K\u03b1 H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3K\u03b1 H1047R-mutant breast cancer models. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-p4-08-02 (2023).","journal-title":"Cancer Res."},{"key":"1388_CR195","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/2159-8290.CD-23-0944","volume":"14","author":"A Varkaris","year":"2024","unstructured":"Varkaris, A. et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3K\u03b1 inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discov. 14, 240\u2013257 (2024).","journal-title":"Cancer Discov."},{"key":"1388_CR196","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.csbj.2024.07.010","volume":"23","author":"DM Kotzampasi","year":"2024","unstructured":"Kotzampasi, D. M., Papadourakis, M., Burke, J. E. & Cournia, Z. Free energy landscape of the PI3K\u03b1 C-terminal activation. Comput. Struct. Biotechnol. J. 23, 3118\u20133131 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1388_CR197","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1538-7445.AM2025-3004","volume":"85","author":"AC Smith","year":"2025","unstructured":"Smith, A. C. et al. Abstract 3004: preclinical characterization of CGT6297, a novel PI3K\u03b1 H1047R mutant-selective inhibitor. Cancer Res. 85, 3004\u20133004 (2025).","journal-title":"Cancer Res."},{"key":"1388_CR198","doi-asserted-by":"publisher","first-page":"LB437","DOI":"10.1158\/1538-7445.AM2025-LB437","volume":"85","author":"M Li","year":"2025","unstructured":"Li, M. et al. Abstract LB437: LAE118, a pan mutant-selective PI3Ka inhibitor with superb activity against both the kinase domain and helical domain mutants. Cancer Res. 85, LB437\u2013LB437 (2025).","journal-title":"Cancer Res."},{"key":"1388_CR199","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/1538-7445.AM2025-3002","volume":"85","author":"X Fan","year":"2025","unstructured":"Fan, X. et al. Abstract 3002: GSC002639, a brain penetrating and mutant-selective PI3K\u03b1 inhibitor, exhibits potent mono- and combination therapy against PI3CA mutant tumors. Cancer Res. 85, 3002\u20133002 (2025).","journal-title":"Cancer Res."},{"key":"1388_CR200","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1158\/1538-7445.AM2025-5977","volume":"85","author":"C Niu","year":"2025","unstructured":"Niu, C. et al. Abstract 5977: identification and characterization of an allosteric and mutant-selective PI3K\u03b1 inhibitor. Cancer Res. 85, 5977\u20135977 (2025).","journal-title":"Cancer Res."},{"key":"1388_CR201","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2025.43.16_suppl.1086","volume":"43","author":"SL Sammons","year":"2025","unstructured":"Sammons, S. L. et al. Updated efficacy of mutant-selective PI3K\u03b1 inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2\u2013 advanced breast cancer: ReDiscover trial. J. Clin. Oncol. 43, 1086 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1388_CR202","doi-asserted-by":"publisher","first-page":"S1220","DOI":"10.1016\/j.annonc.2024.08.2266","volume":"35","author":"AJ Montero","year":"2024","unstructured":"Montero, A. J. et al. LBA27 first-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients. Ann. Oncol. 35, S1220 (2024).","journal-title":"Ann. Oncol."},{"key":"1388_CR203","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","volume":"14","author":"A Varkaris","year":"2024","unstructured":"Varkaris, A. et al. Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 14, 227\u2013239 (2024).","journal-title":"Cancer Discov."},{"key":"1388_CR204","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2025-3092","volume":"146","author":"S Crary","year":"2025","unstructured":"Crary, S. et al. ReInspire: a phase 2 study of mutant-selective PI3K\u03b1 inhibitor, RLY-2608, in adults and children with PIK3CA-related overgrowth spectrum and malformations driven by PIK3CA mutation. Blood 146, 3092 (2025).","journal-title":"Blood"},{"key":"1388_CR205","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.str.2024.03.007","volume":"32","author":"X Huang","year":"2024","unstructured":"Huang, X. et al. Cryo-EM structures reveal two allosteric inhibition modes of PI3K\u03b1(H1047R) involving a re-shaping of the activation loop. Structure 32, 907\u2013917.e7 (2024).","journal-title":"Structure"},{"key":"1388_CR206","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2159-8290.CD-23-1392","volume":"14","author":"GQ Gong","year":"2024","unstructured":"Gong, G. Q. & Vanhaesebroeck, B. Precision targeting of mutant PI3K\u03b1. Cancer Discov. 14, 204\u2013207 (2024).","journal-title":"Cancer Discov."},{"key":"1388_CR207","doi-asserted-by":"publisher","first-page":"CT017","DOI":"10.1158\/1538-7445.AM2023-CT017","volume":"83","author":"A Varkaris","year":"2023","unstructured":"Varkaris, A. et al. Abstract CT017: pan-mutant and isoform selective PI3K\u03b1 inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial. Cancer Res. 83, CT017 (2023).","journal-title":"Cancer Res."},{"key":"1388_CR208","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie, T. A. Targeted covalent inhibitors for drug design. Angew. Chem. Int. Ed. Engl. 55, 13408\u201313421 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1388_CR209","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/med.22084","volume":"45","author":"Z Zhao","year":"2025","unstructured":"Zhao, Z. & Bourne, P. E. Advances in reversible covalent kinase inhibitors. Med. Res. Rev. 45, 629\u2013653 (2025).","journal-title":"Med. Res. Rev."},{"key":"1388_CR210","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1039\/D1MD00068C","volume":"12","author":"H Kim","year":"2021","unstructured":"Kim, H., Hwang, Y. S., Kim, M. & Park, S. B. Recent advances in the development of covalent inhibitors. RSC Med. Chem. 12, 1037\u20131045 (2021).","journal-title":"RSC Med. Chem."},{"key":"1388_CR211","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1128\/MCB.16.4.1722","volume":"16","author":"MP Wymann","year":"1996","unstructured":"Wymann, M. P. et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16, 1722\u20131733 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"1388_CR212","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/jm3008745","volume":"56","author":"M Nacht","year":"2013","unstructured":"Nacht, M. et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3K\u03b1. J. Med. Chem. 56, 712\u2013721 (2013).","journal-title":"J. Med. Chem."},{"key":"1388_CR213","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1021\/jacs.1c13568","volume":"144","author":"C Borsari","year":"2022","unstructured":"Borsari, C. et al. Covalent proximity scanning of a distal cysteine to target PI3K\u03b1. J. Am. Chem. Soc. 144, 6326\u20136342 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1388_CR214","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1158\/1538-7445.AM2023-4946","volume":"83","author":"JR MacDougall","year":"2023","unstructured":"MacDougall, J. R., Bradley, J., Mak, R., Dhawan, N. & Chen, W. Abstract 4946: TOS-358, a first-in-class covalent PI3K\u03b1 inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models. Cancer Res. 83, 4946 (2023).","journal-title":"Cancer Res."},{"key":"1388_CR215","doi-asserted-by":"publisher","first-page":"S499","DOI":"10.1016\/j.annonc.2024.08.692","volume":"35","author":"M Fakih","year":"2024","unstructured":"Fakih, M. et al. Initial results from the phase I, first-in-human study of the covalent, PI3K\u03b1 inhibitor TOS-358 in patients with solid tumors, expressing PI3K\u03b1 mutations or amplifications. Ann. Oncol. 35, S499\u2013S500 (2024).","journal-title":"Ann. Oncol."},{"key":"1388_CR216","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1021\/acschembio.1c00225","volume":"16","author":"JCL Fournier","year":"2021","unstructured":"Fournier, J. C. L. et al. Acetylation of the catalytic lysine inhibits kinase activity in PI3K\u03b4. ACS Chem. Biol. 16, 1644\u20131653 (2021).","journal-title":"ACS Chem. Biol."},{"key":"1388_CR217","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1021\/jacs.7b08979","volume":"140","author":"SE Dalton","year":"2018","unstructured":"Dalton, S. E. et al. Selectively targeting the kinome-conserved lysine of PI3K\u03b4 as a general approach to covalent kinase inhibition. J. Am. Chem. Soc. 140, 932\u2013939 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1388_CR218","doi-asserted-by":"publisher","first-page":"20076","DOI":"10.1021\/acs.jmedchem.4c01284","volume":"67","author":"B Yuan","year":"2024","unstructured":"Yuan, B. et al. Lysine-targeted covalent inhibitors of PI3K\u03b4 synthesis and screening by in situ interaction upgradation. J. Med. Chem. 67, 20076\u201320099 (2024).","journal-title":"J. Med. Chem."},{"key":"1388_CR219","doi-asserted-by":"publisher","first-page":"117948","DOI":"10.1016\/j.ejmech.2025.117948","volume":"297","author":"B Yuan","year":"2025","unstructured":"Yuan, B. et al. Discovery of novel covalent PI3K\u03b4 inhibitors bearing alaninamide moiety by lysine-targeted covalent strategy. Eur. J. Med. Chem. 297, 117948 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"1388_CR220","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41586-024-08176-4","volume":"637","author":"GB Craven","year":"2025","unstructured":"Craven, G. B. et al. Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation. Nature 637, 205\u2013214 (2025).","journal-title":"Nature"},{"key":"1388_CR221","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41573-024-00197-y","volume":"24","author":"A Eccleston","year":"2025","unstructured":"Eccleston, A. Covalent inhibitor engages oncogenic AKT kinase. Nat. Rev. Drug. Discov. 24, 16 (2025).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1388_CR222","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1002\/anie.201502142","volume":"54","author":"J Weisner","year":"2015","unstructured":"Weisner, J. et al. Covalent-allosteric kinase inhibitors. Angew. Chem. Int. Ed. Engl. 54, 10313\u201310316 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1388_CR223","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1021\/acs.jmedchem.5b00991","volume":"58","author":"A Fouque","year":"2015","unstructured":"Fouque, A. et al. A novel covalent mTOR inhibitor, DHM25, shows in vivo antitumor activity against triple-negative breast cancer cells. J. Med. Chem. 58, 6559\u20136573 (2015).","journal-title":"J. Med. Chem."},{"key":"1388_CR224","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jmb.2017.01.023","volume":"429","author":"ML Mohan","year":"2017","unstructured":"Mohan, M. L. & Naga Prasad, S. V. Scaffolding function of PI3K\u03b3 emerges from Enzyme\u2019s shadow. J. Mol. Biol. 429, 763\u2013772 (2017).","journal-title":"J. Mol. Biol."},{"key":"1388_CR225","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejmech.2018.03.066","volume":"151","author":"W Li","year":"2018","unstructured":"Li, W. et al. Phthalimide conjugations for the degradation of oncogenic PI3K. Eur. J. Med. Chem. 151, 237\u2013247 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1388_CR226","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1039\/D3SC04629J","volume":"15","author":"WT Jauslin","year":"2024","unstructured":"Jauslin, W. T. et al. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3K\u03b1. Chem. Sci. 15, 683\u2013691 (2024).","journal-title":"Chem. Sci."},{"key":"1388_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 598, 217112 (2024).","journal-title":"Cancer Lett."},{"key":"1388_CR228","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c03169","author":"J Cen","year":"2025","unstructured":"Cen, J. et al. Double swords in one: novel selective PI3K\/110\u03b2 PROTAC degraders for the treatment of multidrug-resistant cancer by activating ERS and inhibiting P-gp. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c03169 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR229","doi-asserted-by":"publisher","first-page":"11437","DOI":"10.1021\/acs.jmedchem.5c00408","volume":"68","author":"B Yuan","year":"2025","unstructured":"Yuan, B. et al. Lysine-targeted covalent strategy leading to the discovery of novel potent PROTAC-based PI3K\u03b4 degraders. J. Med. Chem. 68, 11437\u201311467 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR230","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adf2670","volume":"17","author":"EC Erickson","year":"2024","unstructured":"Erickson, E. C. et al. Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Sci. Signal. 17, eadf2670 (2024).","journal-title":"Sci. Signal."},{"key":"1388_CR231","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/2159-8290.CD-20-0815","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. AKT degradation selectively inhibits the growth of PI3K\/PTEN pathway-mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B. Cancer Discov. 11, 3064\u20133089 (2021).","journal-title":"Cancer Discov."},{"key":"1388_CR232","doi-asserted-by":"publisher","first-page":"18054","DOI":"10.1021\/acs.jmedchem.1c01476","volume":"64","author":"X Yu","year":"2021","unstructured":"Yu, X. et al. Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders. J. Med. Chem. 64, 18054\u201318081 (2021).","journal-title":"J. Med. Chem."},{"key":"1388_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114459","volume":"238","author":"CL Zhu","year":"2022","unstructured":"Zhu, C. L. et al. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader. Eur. J. Med. Chem. 238, 114459 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1388_CR234","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.chembiol.2019.11.014","volume":"27","author":"I You","year":"2020","unstructured":"You, I. et al. Discovery of an AKT degrader with prolonged inhibition of downstream signaling. Cell Chem. Biol. 27, 66\u201373.e7 (2020).","journal-title":"Cell Chem. Biol."},{"key":"1388_CR235","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/psc.2858","volume":"22","author":"RK Henning","year":"2016","unstructured":"Henning, R. K. et al. Degradation of Akt using protein-catalyzed capture agents. J. Pept. Sci. 22, 196\u2013200 (2016).","journal-title":"J. Pept. Sci."},{"key":"1388_CR236","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1248\/cpb.c22-00576","volume":"71","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Design, synthesis, and biological evaluation of mTOR-targeting PROTACs based on MLN0128 and pomalidomide. Chem. Pharm. Bull. 71, 120\u2013128 (2023).","journal-title":"Chem. Pharm. Bull."},{"key":"1388_CR237","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c02244","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Discovery of the first potent PI3K\/mTOR dual-targeting PROTAC degrader for efficient modulation of the PI3K\/AKT\/mTOR pathway. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02244 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR238","doi-asserted-by":"publisher","first-page":"24404","DOI":"10.1021\/acs.jmedchem.5c02352","volume":"68","author":"Y Hou","year":"2025","unstructured":"Hou, Y. et al. Structure-guided design of a highly selective PI3K\u03b1 inhibitor overcoming metabolic dysregulation with potent anti-breast cancer efficacy. J. Med. Chem. 68, 24404\u201324423 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR239","doi-asserted-by":"publisher","first-page":"18260","DOI":"10.1074\/jbc.270.31.18260","volume":"270","author":"D Hartley","year":"1995","unstructured":"Hartley, D., Meisner, H. & Corvera, S. Specific association of the \u03b2 isoform of the p85 subunit of phosphatidylinositol-3 kinase with the proto-oncogene c-cbl. J. Biol. Chem. 270, 18260\u201318263 (1995).","journal-title":"J. Biol. Chem."},{"key":"1388_CR240","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/ncb2731","volume":"15","author":"S Kuchay","year":"2013","unstructured":"Kuchay, S. et al. FBXL2- and PTPL1-mediated degradation of p110-free p85\u03b2 regulatory subunit controls the PI(3)K signalling cascade. Nat. Cell Biol. 15, 472\u2013480 (2013).","journal-title":"Nat. Cell Biol."},{"key":"1388_CR241","doi-asserted-by":"publisher","first-page":"11381","DOI":"10.1073\/pnas.0906461107","volume":"107","author":"LC Foukas","year":"2010","unstructured":"Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107, 11381\u201311386 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR242","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.cmet.2019.03.010","volume":"29","author":"A Molinaro","year":"2019","unstructured":"Molinaro, A. et al. Insulin-driven PI3K-AKT signaling in the hepatocyte is mediated by redundant PI3K\u03b1 and PI3K\u03b2 activities and is promoted by RAS. Cell Metab. 29, 1400\u20131409.e5 (2019).","journal-title":"Cell Metab."},{"key":"1388_CR243","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1038\/s41436-021-01290-y","volume":"23","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel\u2013Trenaunay syndrome (KTS): the TOTEM trial, a phase 1\/2 multicenter, open-label, single-arm study. Genet. Med. 23, 2433\u20132442 (2021).","journal-title":"Genet. Med."},{"key":"1388_CR244","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1078-0432.CCR-17-0042","volume":"24","author":"QW Fan","year":"2018","unstructured":"Fan, Q. W., Nicolaides, T. P. & Weiss, W. A. Inhibiting 4EBP1 in glioblastoma. Clin. Cancer Res. 24, 14\u201321 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR245","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","volume":"31","author":"Q Fan","year":"2017","unstructured":"Fan, Q. et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell 31, 424\u2013435 (2017).","journal-title":"Cancer Cell"},{"key":"1388_CR246","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature17963","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","unstructured":"Rodrik-Outmezguine, V. S. et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534, 272\u2013276 (2016).","journal-title":"Nature"},{"key":"1388_CR247","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1021\/acs.jmedchem.2c01658","volume":"66","author":"GL Burnett","year":"2023","unstructured":"Burnett, G. L. et al. Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors. J. Med. Chem. 66, 149\u2013169 (2023).","journal-title":"J. Med. Chem."},{"key":"1388_CR248","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-25-2112","volume":"31","author":"AM Schram","year":"2025","unstructured":"Schram, A. M. et al. The bi-steric, mTORC1-selective inhibitor, RMC-5552, in advanced solid tumors: a phase 1 trial. Clin. Cancer Res. 31, 4933\u20134943 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR249","doi-asserted-by":"publisher","first-page":"S1677","DOI":"10.1016\/j.annonc.2025.09.027","volume":"36","author":"SA Hurvitz","year":"2025","unstructured":"Hurvitz, S. A. et al. LBA17 Gedatolisib (geda)\u2009+\u2009fulvestrant\u2009\u00b1\u2009palbociclib (palbo) vs fulvestrant in patients (pts) with HR+\/ HER2\u2013\/PIK3CA wild-type (WT) advanced breast cancer (ABC): first results from VIKTORIA-1. Ann. Oncol. 36, S1677\u2013S1678 (2025).","journal-title":"Ann. Oncol."},{"key":"1388_CR250","unstructured":"Celcuity. Celcuity announces completion of submission of its new drug application to the U.S. FDA for gedatolisib in HR+\/HER2\u2013\/PIK3CA wild-type advanced breast cancer. SaintPaul Press https:\/\/www.thesaintpaulpress.com\/article\/868023096-celcuity-announces-completion-of-submission-of-its-new-drug-application-to-the-u-s-fda-for-gedatolisib-in-hr-her2-pik3ca-wild-type-advanced-breast (2025)."},{"key":"1388_CR251","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1021\/acs.jmedchem.5b01655","volume":"59","author":"ME Van Dort","year":"2016","unstructured":"Van Dort, M. E. et al. Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K). J. Med. Chem. 59, 2512\u20132522 (2016).","journal-title":"J. Med. Chem."},{"key":"1388_CR252","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","volume":"18","author":"S Joshi","year":"2019","unstructured":"Joshi, S. et al. SF2523: dual PI3K\/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer. Mol. Cancer Ther. 18, 1036\u20131044 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR253","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1021\/acs.jmedchem.4c02478","volume":"68","author":"K Ran","year":"2025","unstructured":"Ran, K. et al. Design, synthesis, and biological evaluation of Thieno[3,2-d]pyrimidine derivatives as the first bifunctional PI3K\u03b4 isoform selective\/bromodomain and extra-terminal inhibitors. J. Med. Chem. 68, 3260\u20133281 (2025).","journal-title":"J. Med. Chem."},{"key":"1388_CR254","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","volume":"18","author":"C Qian","year":"2012","unstructured":"Qian, C. et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res. 18, 4104\u20134113 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR255","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00044-020-02502-x","volume":"29","author":"Q Tao","year":"2020","unstructured":"Tao, Q. et al. A conjugated mTOR\/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery. Med. Chem. Res. 29, 519\u2013527 (2020).","journal-title":"Med. Chem. Res."},{"key":"1388_CR256","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1016\/j.celrep.2018.12.003","volume":"25","author":"MM Murillo","year":"2018","unstructured":"Murillo, M. M. et al. Disruption of the Interaction of RAS with PI 3-kinase induces regression of EGFR-mutant-driven lung cancer. Cell Rep. 25, 3545\u20133553.e2 (2018).","journal-title":"Cell Rep."},{"key":"1388_CR257","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.cell.2007.03.051","volume":"129","author":"S Gupta","year":"2007","unstructured":"Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110\u03b1 is required for ras-driven tumorigenesis in mice. Cell 129, 957\u2013968 (2007).","journal-title":"Cell"},{"key":"1388_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11245","volume":"7","author":"E Castellano","year":"2016","unstructured":"Castellano, E. et al. RAS signalling through PI3-kinase controls cell migration via modulation of Reelin expression. Nat. Commun. 7, 11245 (2016).","journal-title":"Nat. Commun."},{"key":"1388_CR259","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55766-x","volume":"16","author":"D Czyzyk","year":"2025","unstructured":"Czyzyk, D. et al. Structural insights into isoform-specific RAS\u2013PI3K\u03b1 interactions and the role of RAS in PI3K\u03b1 activation. Nat. Commun. 16, 525 (2025).","journal-title":"Nat. Commun."},{"key":"1388_CR260","doi-asserted-by":"publisher","unstructured":"Torosyan, H. et al. Structures of the PI3K\u03b1\/KRas complex on lipid bilayers reveal the molecular mechanism of PI3K\u03b1 activation. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.03.22.644753 (2025).","DOI":"10.1101\/2025.03.22.644753"},{"key":"1388_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28756-0","volume":"13","author":"M Ismail","year":"2023","unstructured":"Ismail, M. et al. Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110\u03b1. Sci. Rep. 13, 1889 (2023).","journal-title":"Sci. Rep."},{"key":"1388_CR262","doi-asserted-by":"publisher","first-page":"100197","DOI":"10.1016\/j.slasd.2024.100197","volume":"29","author":"M Ismail","year":"2024","unstructured":"Ismail, M. et al. High throughput application of the NanoBiT biochemical assay for the discovery of selective inhibitors of the interaction of PI3K-p110\u03b1 with KRAS. SLAS Discov. 29, 100197 (2024).","journal-title":"SLAS Discov."},{"key":"1388_CR263","unstructured":"Halford, B. A breakup strategy that\u2019s inspiring clinical candidates for cancer. C&EN https:\/\/cen.acs.org\/biological-chemistry\/cancer\/breakup-strategy-clinical-candidates\/103\/web\/2025\/11 (2025)."},{"key":"1388_CR264","doi-asserted-by":"publisher","DOI":"10.1126\/science.adq2004","author":"DK Simanshu","year":"2025","unstructured":"Simanshu, D. K. et al. BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS\u2013PI3K\u03b1 interaction. Science https:\/\/doi.org\/10.1126\/science.adq2004 (2025).","journal-title":"Science"},{"key":"1388_CR265","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv2684","author":"JE Klebba","year":"2025","unstructured":"Klebba, J. E. et al. Covalent inhibitors of the PI3K\u03b1 RAS binding domain impair tumor growth driven by RAS and HER2. Science https:\/\/doi.org\/10.1126\/science.adv2684 (2025).","journal-title":"Science"},{"key":"1388_CR266","unstructured":"Frontier Medicines. Frontier Medicines presents preclinical data from three programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets. frontiermeds.com https:\/\/www.frontiermeds.com\/press-release\/frontier-medicines-presents-preclinical-data-from-three-programs-at-the-37th-aacr-nci-eortc-international-conference-on-molecular-targets\/ (2025)."},{"key":"1388_CR267","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2217\/rme-2019-0065","volume":"15","author":"GA Borges","year":"2020","unstructured":"Borges, G. A. et al. Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration. Regen. Med. 15, 1329\u20131344 (2020).","journal-title":"Regen. Med."},{"key":"1388_CR268","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3892\/ijo.2016.3710","volume":"49","author":"S Matsuda","year":"2016","unstructured":"Matsuda, S. et al. Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy [Review]. Int. J. Oncol. 49, 1785\u20131790 (2016).","journal-title":"Int. J. Oncol."},{"key":"1388_CR269","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3988\/jcn.2015.11.4.297","volume":"11","author":"SH Koh","year":"2015","unstructured":"Koh, S. H. & Lo, E. H. The role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction. J. Clin. Neurol. 11, 297\u2013304 (2015).","journal-title":"J. Clin. Neurol."},{"key":"1388_CR270","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cardiores.2003.09.024","volume":"61","author":"DJ Hausenloy","year":"2004","unstructured":"Hausenloy, D. J. & Yellon, D. M. New directions for protecting the heart against ischaemia\u2013reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61, 448\u2013460 (2004).","journal-title":"Cardiovasc. Res."},{"key":"1388_CR271","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/CIRCRESAHA.116.309278","volume":"120","author":"L Catanese","year":"2017","unstructured":"Catanese, L., Tarsia, J. & Fisher, M. Acute ischemic stroke therapy overview. Circ. Res. 120, 541\u2013558 (2017).","journal-title":"Circ. Res."},{"key":"1388_CR272","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3174\/ajnr.A7177","volume":"42","author":"F Bala","year":"2021","unstructured":"Bala, F. et al. Infarct growth despite successful endovascular reperfusion in acute ischemic stroke: a meta-analysis. AJNR Am. J. Neuroradiol. 42, 1472\u20131478 (2021).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1388_CR273","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","volume":"17","author":"G Heusch","year":"2020","unstructured":"Heusch, G. Myocardial ischaemia\u2013reperfusion injury and cardioprotection in perspective. Nat. Rev. Cardiol. 17, 773\u2013789 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1388_CR274","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80754-8","volume":"11","author":"A Chauhan","year":"2021","unstructured":"Chauhan, A. et al. PTEN inhibitor bpV(HOpic) confers protection against ionizing radiation. Sci. Rep. 11, 1720 (2021).","journal-title":"Sci. Rep."},{"key":"1388_CR275","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133125","volume":"5","author":"T Iosifidis","year":"2020","unstructured":"Iosifidis, T. et al. Aberrant cell migration contributes to defective airway epithelial repair in childhood wheeze. JCI Insight 5, e133125 (2020).","journal-title":"JCI Insight"},{"key":"1388_CR276","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1091\/mbc.E19-05-0303","volume":"31","author":"M Arnes","year":"2020","unstructured":"Arnes, M., Romero, N., Casas-Tinto, S., Acebes, A. & Ferrus, A. PI3K activation prevents A\u03b242-induced synapse loss and favors insoluble amyloid deposit formation. Mol. Biol. Cell 31, 244\u2013260 (2020).","journal-title":"Mol. Biol. Cell"},{"key":"1388_CR277","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1523\/JNEUROSCI.4477-10.2011","volume":"31","author":"G Cuesto","year":"2011","unstructured":"Cuesto, G. et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J. Neurosci. 31, 2721\u20132733 (2011).","journal-title":"J. Neurosci."},{"key":"1388_CR278","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuroscience.2017.10.002","volume":"370","author":"D Asua","year":"2018","unstructured":"Asua, D., Bougamra, G., Calleja-Felipe, M., Morales, M. & Knafo, S. Peptides acting as cognitive enhancers. Neuroscience 370, 81\u201387 (2018).","journal-title":"Neuroscience"},{"key":"1388_CR279","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911674","volume":"12","author":"B Nieuwenhuis","year":"2020","unstructured":"Nieuwenhuis, B. et al. PI 3-kinase \u03b4 enhances axonal PIP3 to support axon regeneration in the adult CNS. EMBO Mol. Med. 12, e11674 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1388_CR280","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350446","volume":"53","author":"WJ Yeoh","year":"2023","unstructured":"Yeoh, W. J. & Krebs, P. SHIP1 and its role for innate immune regulation \u2014 novel targets for immunotherapy. Eur. J. Immunol. 53, e2350446 (2023).","journal-title":"Eur. J. Immunol."},{"key":"1388_CR281","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/molecules23020285","volume":"23","author":"R Pulido","year":"2018","unstructured":"Pulido, R. PTEN inhibition in human disease therapy. Molecules 23, 285 (2018).","journal-title":"Molecules"},{"key":"1388_CR282","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/13543776.2019.1669562","volume":"29","author":"CS Boosani","year":"2019","unstructured":"Boosani, C. S., Gunasekar, P. & Agrawal, D. K. An update on PTEN modulators \u2014 a patent review. Expert. Opin. Ther. Pat. 29, 881\u2013889 (2019).","journal-title":"Expert. Opin. Ther. Pat."},{"key":"1388_CR283","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/cancers13040890","volume":"13","author":"C Pedicone","year":"2021","unstructured":"Pedicone, C., Meyer, S. T., Chisholm, J. D. & Kerr, W. G. Targeting SHIP1 and SHIP2 in cancer. Cancers 13, 890 (2021).","journal-title":"Cancers"},{"key":"1388_CR284","doi-asserted-by":"publisher","first-page":"123101","DOI":"10.1016\/j.lfs.2024.123101","volume":"357","author":"A El Sayed","year":"2024","unstructured":"El Sayed, A., Gomes, N., Czerwinska, A. & Azzi, A. Drugs targeting SHIP2 demonstrate potent antiproliferative effects irrespective of SHIP2 inhibition. Life Sci. 357, 123101 (2024).","journal-title":"Life Sci."},{"key":"1388_CR285","doi-asserted-by":"publisher","first-page":"116756","DOI":"10.1016\/j.bcp.2025.116756","volume":"233","author":"K Premeti","year":"2025","unstructured":"Premeti, K. et al. First generation vanadium-based PTEN inhibitors: comparative study in vitro and in vivo and identification of a novel mechanism of action. Biochem. Pharmacol. 233, 116756 (2025).","journal-title":"Biochem. Pharmacol."},{"key":"1388_CR286","doi-asserted-by":"publisher","first-page":"117965","DOI":"10.1016\/j.bmc.2024.117965","volume":"114","author":"J Miao","year":"2024","unstructured":"Miao, J. et al. Discovery and evaluation of novel SHIP-1 inhibitors. Bioorg Med. Chem. 114, 117965 (2024).","journal-title":"Bioorg Med. Chem."},{"key":"1388_CR287","volume":"9","author":"CD Jesudason","year":"2023","unstructured":"Jesudason, C. D. et al. SHIP1 therapeutic target enablement: identification and evaluation of inhibitors for the treatment of late-onset Alzheimer\u2019s disease. Alzheimers Dement. 9, e12429 (2023).","journal-title":"Alzheimers Dement."},{"key":"1388_CR288","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05972-2","volume":"618","author":"GQ Gong","year":"2023","unstructured":"Gong, G. Q. et al. A small-molecule PI3K\u03b1 activator for cardioprotection and neuroregeneration. Nature 618, 159\u2013168 (2023).","journal-title":"Nature"},{"key":"1388_CR289","doi-asserted-by":"publisher","first-page":"101060","DOI":"10.1016\/j.jbior.2024.101060","volume":"95","author":"GQ Gong","year":"2025","unstructured":"Gong, G. Q. et al. Making PI3K superfamily enzymes run faster. Adv. Biol. Regul. 95, 101060 (2025).","journal-title":"Adv. Biol. Regul."},{"key":"1388_CR290","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1126\/science.adr9097","volume":"389","author":"K Terayama","year":"2025","unstructured":"Terayama, K. et al. Molecular glues that facilitate RAS binding to PI3K\u03b1 promote glucose uptake without insulin. Science 389, 402\u2013408 (2025).","journal-title":"Science"},{"key":"1388_CR291","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1073\/pnas.1202810109","volume":"109","author":"H Jo","year":"2012","unstructured":"Jo, H. et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc. Natl Acad. Sci. USA 109, 10581\u201310586 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR292","doi-asserted-by":"publisher","first-page":"60123","DOI":"10.18632\/oncotarget.11164","volume":"7","author":"YQ Gong","year":"2016","unstructured":"Gong, Y. Q. et al. SC79 protects retinal pigment epithelium cells from UV radiation via activating Akt\u2013Nrf2 signaling. Oncotarget 7, 60123\u201360132 (2016).","journal-title":"Oncotarget"},{"key":"1388_CR293","doi-asserted-by":"publisher","first-page":"12639","DOI":"10.18632\/oncotarget.23538","volume":"9","author":"Y Xu","year":"2018","unstructured":"Xu, Y., Gao, Y. W. & Yang, Y. SC79 protects dopaminergic neurons from oxidative stress. Oncotarget 9, 12639\u201312648 (2018).","journal-title":"Oncotarget"},{"key":"1388_CR294","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.12659\/MSM.911178","volume":"24","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Protective effects the Akt activator SC79 in hepatic ischemia\u2013reperfusion injury. Med. Sci. Monit. 24, 4346\u20134354 (2018).","journal-title":"Med. Sci. Monit."},{"key":"1388_CR295","doi-asserted-by":"publisher","first-page":"31065","DOI":"10.18632\/oncotarget.16075","volume":"8","author":"YX Chen","year":"2017","unstructured":"Chen, Y. X. et al. Novel Akt activator SC-79 is a potential treatment for alcohol-induced osteonecrosis of the femoral head. Oncotarget 8, 31065\u201331078 (2017).","journal-title":"Oncotarget"},{"key":"1388_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40693-5","volume":"9","author":"S Sengupta","year":"2019","unstructured":"Sengupta, S. et al. Discovery of NV-5138, the first selective brain mTORC1 activator. Sci. Rep. 9, 4107 (2019).","journal-title":"Sci. Rep."},{"key":"1388_CR297","unstructured":"Supernus. Supernus and Navitor announce development and option agreement for orally active mTORC1 activator NV-5138. Supernus.com https:\/\/ir.supernus.com\/news-releases\/news-release-details\/supernus-and-navitor-announce-development-and-option-agreement (2020)."},{"key":"1388_CR298","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.celrep.2014.10.019","volume":"9","author":"A Parmigiani","year":"2014","unstructured":"Parmigiani, A. et al. Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Rep. 9, 1281\u20131291 (2014).","journal-title":"Cell Rep."},{"key":"1388_CR299","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1172\/JCI126859","volume":"129","author":"T Kato","year":"2019","unstructured":"Kato, T. et al. Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J. Clin. Invest. 129, 2542\u20132554 (2019).","journal-title":"J. Clin. Invest."},{"key":"1388_CR300","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch, C. et al. Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117\u20131129 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1388_CR301","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase \u03b1 inhibitor selected for clinical evaluation. Bioorg Med. Chem. Lett. 23, 3741\u20133748 (2013).","journal-title":"Bioorg Med. Chem. Lett."},{"key":"1388_CR302","unstructured":"Braun, M.-G. et al. Benzoxazepin oxazolidinone compounds and methods of use. Patent WO2017001645 (2017); https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US9643980."},{"key":"1388_CR303","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1016\/j.tet.2019.04.057","volume":"75","author":"C Han","year":"2019","unstructured":"Han, C. et al. Synthesis of PI3K inhibitor GDC-0077 via a stereocontrolled N-arylation of \u03b1-amino acids. Tetrahedron 75, 4351\u20134357 (2019).","journal-title":"Tetrahedron"},{"key":"1388_CR304","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/j.annonc.2020.08.457","volume":"31","author":"N Turner","year":"2020","unstructured":"Turner, N. et al. Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant\/hormone receptor-positive\/HER2-negative locally advanced or metastatic breast cancer (HR+\/HER2\u2013LA\/MBC). Ann. Oncol. 31, S391\u2013S392 (2020).","journal-title":"Ann. Oncol."},{"key":"1388_CR305","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs19-Ot1-08-04","author":"D Juric","year":"2020","unstructured":"Juric, D. et al. A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-Ot1-08-04 (2020).","journal-title":"Cancer Res."},{"key":"1388_CR306","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/1538-7445.AM2017-156","volume":"77","author":"K Edgar","year":"2017","unstructured":"Edgar, K. et al. Preclinical characterization of GDC-0077, a specific PI3K\u03b1 inhibitor in early clinical development. Cancer Res. 77, 156 (2017).","journal-title":"Cancer Res."},{"key":"1388_CR307","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti, B. J. et al. CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591\u2013594 (2011).","journal-title":"Blood"},{"key":"1388_CR308","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","volume":"20","author":"DG Winkler","year":"2013","unstructured":"Winkler, D. G. et al. PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364\u20131374 (2013).","journal-title":"Chem. Biol."},{"key":"1388_CR309","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","volume":"19","author":"HA Burris","year":"2018","unstructured":"Burris, H. A. et al. Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet. Oncol. 19, 486\u2013496 (2018).","journal-title":"Lancet. Oncol."},{"key":"1388_CR310","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","volume":"8","author":"K Hoegenauer","year":"2017","unstructured":"Hoegenauer, K. et al. Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K\u03b4-selective inhibitors. ACS Med. Chem. Lett. 8, 975\u2013980 (2017).","journal-title":"ACS Med. Chem. Lett."},{"key":"1388_CR311","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03669-2","volume":"25","author":"P Sun","year":"2025","unstructured":"Sun, P. et al. PI3K\u03b4 inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib\/II trial. Cancer Cell Int. 25, 39 (2025).","journal-title":"Cancer Cell Int."},{"key":"1388_CR312","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cmdc.201600148","volume":"11","author":"WJ Scott","year":"2016","unstructured":"Scott, W. J. et al. Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem 11, 1517\u20131530 (2016).","journal-title":"ChemMedChem"},{"key":"1388_CR313","doi-asserted-by":"publisher","first-page":"S499","DOI":"10.1016\/j.annonc.2024.08.692","volume":"35","author":"M Fakih","year":"2024","unstructured":"Fakih, M. et al. 625P Initial results from the phase I, first-in-human study of the covalent, PI3K\u03b1 inhibitor TOS-358 in patients with solid tumors, expressing PI3K\u03b1 mutations or amplifications. Ann. Oncol. 35, S499\u2013S500 (2024).","journal-title":"Ann. Oncol."},{"key":"1388_CR314","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34782-9","volume":"13","author":"XL Wei","year":"2022","unstructured":"Wei, X. L. et al. First-in-human phase Ia study of the PI3K\u03b1 inhibitor CYH33 in patients with solid tumors. Nat. Commun. 13, 7012 (2022).","journal-title":"Nat. Commun."},{"key":"1388_CR315","doi-asserted-by":"publisher","first-page":"S372","DOI":"10.1016\/j.annonc.2025.08.890","volume":"36","author":"M Yan","year":"2025","unstructured":"Yan, M. et al. 466P Efficacy and safety of JS105, a selective inhibitor of mutant PI3K\u03b1, in patients with advanced cancer. Ann. Oncol. 36, S372 (2025).","journal-title":"Ann. Oncol."},{"key":"1388_CR316","doi-asserted-by":"publisher","first-page":"21849","DOI":"10.1002\/cam4.6755","volume":"12","author":"Q Ouyang","year":"2023","unstructured":"Ouyang, Q. et al. HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: a phase 1 dose-escalation trial. Cancer Med. 12, 21849\u201321860 (2023).","journal-title":"Cancer Med."},{"key":"1388_CR317","unstructured":"Ensem Therapeutics announces ETX-636 granted Fast Track designation by the FDA for advanced breast cancer. Business Wire (1 October 2025); https:\/\/www.businesswire.com\/news\/home\/20251001083267\/en\/Ensem-Therapeutics-Announces-ETX-636-Granted-Fast-Track-Designation-by-the-FDA-for-Advanced-Breast-Cancer."},{"key":"1388_CR318","doi-asserted-by":"publisher","first-page":"P3-08-19-P03-08","DOI":"10.1158\/1557-3265.SABCS24-P3-08-19","volume":"31","author":"S Agresta","year":"2025","unstructured":"Agresta, S. et al. Abstract P3-08-19: preliminary results from PIKture-01, a first-in-human study of OKI-219, a mutant selective inhibitor of PI3K\u03b1-H1047R, in mutant selected solid tumors including breast cancer. Clin. Cancer Res. 31, P3-08-19-P03-08-19 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR319","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2014.00233","volume":"5","author":"P Haselmayer","year":"2014","unstructured":"Haselmayer, P. et al. Characterization of novel PI3K\u03b4 inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Front. Immunol. 5, 233 (2014).","journal-title":"Front. Immunol."},{"key":"1388_CR320","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1158\/1538-7445.AM2019-2692","volume":"79","author":"K Ewings","year":"2019","unstructured":"Ewings, K. et al. Abstract 2692: preclinical development of a novel, highly selective PI3K\u03b4 inhibitor, IOA-244, for the treatment of solid malignancies. Cancer Res. 79, 2692\u20132692 (2019).","journal-title":"Cancer Res."},{"key":"1388_CR321","doi-asserted-by":"publisher","first-page":"1478234","DOI":"10.3389\/fphar.2024.1478234","volume":"15","author":"CY Zhao","year":"2024","unstructured":"Zhao, C. Y. et al. Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3K\u03b4 inhibitor for the treatment of non-hodgkin\u2019s lymphoma, in healthy Chinese volunteers. Front. Pharmacol. 15, 1478234 (2024).","journal-title":"Front. Pharmacol."},{"key":"1388_CR322","doi-asserted-by":"crossref","unstructured":"Cosman, R. et al. A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase \u03b4 (PI3K\u03b4) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors. Presented at the American Association for Cancer Research (AACR) Annual Meeting Poster No. CT189 (2024); https:\/\/www.beonemedinfo.com\/CongressDocuments\/Cosman_BGB-A317-3111-10188-101_AACR_Poster_2024.pdf.","DOI":"10.1158\/1538-7445.AM2024-CT189"},{"key":"1388_CR323","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1158\/1538-7445.AM2016-3331","volume":"76","author":"S Sneha","year":"2016","unstructured":"Sneha, S., Nivetha, R., Srikant, V., Swaroop, V. & Ganesan, T. S. Abstract 3331: RP6530, a dual PI3K \u03b4\/\u03b3 inhibitor attenuates cancer stem cell proliferation in serous adenocarcinoma of ovary. Cancer Res. 76, 3331 (2016).","journal-title":"Cancer Res."},{"key":"1388_CR324","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2019-130401","volume":"134","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil, L. J. et al. Results of a first in human, dose ascending, phase I study examining the safety and tolerability of KA2237, an oral PI3K p110\u03b2\/\u03b4 inhibitor in patients with relapsed\/refractory (R\/R) B-cell lymphoma. Blood 134, 4099 (2019).","journal-title":"Blood"},{"key":"1388_CR325","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1080\/10428194.2021.1957874","volume":"62","author":"LJ Nastoupil","year":"2021","unstructured":"Nastoupil, L. J. et al. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K\u03b2\/\u03b4 in relapsed refractory B cell lymphoma. Leuk. Lymphoma 62, 3452\u20133462 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"1388_CR326","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","volume":"7","author":"CA Evans","year":"2016","unstructured":"Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med. Chem. Lett. 7, 862\u2013867 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"1388_CR327","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41467-026-69225-2","volume":"17","author":"P Zhang","year":"2026","unstructured":"Zhang, P. et al. Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. Nat. Commun. 17, 2456 (2026).","journal-title":"Nat. Commun."},{"key":"1388_CR328","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","volume":"26","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. First-in-human phase I study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin. Cancer Res. 26, 1820\u20131828 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR329","first-page":"159689","volume":"1870","author":"AL Shaw","year":"2025","unstructured":"Shaw, A. L., Barlow-Busch, I. & Burke, J. E. Molecular basis for regulation of the class I phosphoinositide 3-kinases (PI3Ks), and their targeting in human disease. Biochim. Biophysica Acta. Mol. Cell Biol. Lipids 1870, 159689 (2025).","journal-title":"Biochim. Biophysica Acta. Mol. Cell Biol. Lipids"},{"key":"1388_CR330","doi-asserted-by":"publisher","first-page":"12176","DOI":"10.1073\/pnas.1803446115","volume":"115","author":"N Tsolakos","year":"2018","unstructured":"Tsolakos, N. et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc. Natl Acad. Sci. USA 115, 12176\u201312181 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR331","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2025.101128","author":"I Barlow-Busch","year":"2025","unstructured":"Barlow-Busch, I., Walsh, E. E., Nyvall, H. G. & Burke, J. E. Activity and dynamics of p110\u03b1 are not differentially modulated by regulatory subunit isoforms. Adv. Biol. Regul. https:\/\/doi.org\/10.1016\/j.jbior.2025.101128 (2025).","journal-title":"Adv. Biol. Regul."},{"key":"1388_CR332","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.biochem.70.1.535","volume":"70","author":"B Vanhaesebroeck","year":"2001","unstructured":"Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535\u2013602 (2001).","journal-title":"Annu. Rev. Biochem."},{"key":"1388_CR333","doi-asserted-by":"publisher","first-page":"R485","DOI":"10.1016\/j.cub.2008.04.048","volume":"18","author":"L Stephens","year":"2008","unstructured":"Stephens, L., Milne, L. & Hawkins, P. Moving towards a better understanding of chemotaxis. Curr. Biol. 18, R485\u2013R494 (2008).","journal-title":"Curr. Biol."},{"key":"1388_CR334","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13046-024-03207-4","volume":"43","author":"D Hassan","year":"2024","unstructured":"Hassan, D., Menges, C. W., Testa, J. R. & Bellacosa, A. AKT kinases as therapeutic targets. J. Exp. Clin. Cancer Res. 43, 313 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1388_CR335","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu, G. Y. & Sabatini, D. M. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 21, 183\u2013203 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1388_CR336","first-page":"109","volume":"39","author":"L He","year":"2025","unstructured":"He, L., Cho, S. & Blenis, J. mTORC1, the maestro of cell metabolism and growth. Genes. Dev. 39, 109\u2013131 (2025).","journal-title":"Genes. Dev."},{"key":"1388_CR337","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BCJ20220325","volume":"481","author":"A Ragupathi","year":"2024","unstructured":"Ragupathi, A., Kim, C. & Jacinto, E. The mTORC2 signaling network: targets and cross-talks. Biochem. J. 481, 45\u201391 (2024).","journal-title":"Biochem. J."},{"key":"1388_CR338","doi-asserted-by":"publisher","first-page":"104404","DOI":"10.1016\/j.critrevonc.2024.104404","volume":"200","author":"M Sirico","year":"2024","unstructured":"Sirico, M. et al. Navigating the complexity of PI3K\/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond. Crit. Rev. Oncol. Hematol. 200, 104404 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1388_CR339","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cncr.31044","volume":"124","author":"PL Bedard","year":"2018","unstructured":"Bedard, P. L. et al. First-in-human trial of the PI3K\u03b2-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 124, 315\u2013324 (2018).","journal-title":"Cancer"},{"key":"1388_CR340","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211743","volume":"220","author":"J Bhin","year":"2023","unstructured":"Bhin, J. et al. MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer. J. Exp. Med. 220, e20211743 (2023).","journal-title":"J. Exp. Med."},{"key":"1388_CR341","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1158\/1078-0432.CCR-24-2911","volume":"31","author":"Y Yin","year":"2025","unstructured":"Yin, Y. et al. Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia. Clin. Cancer Res. 31, 1943\u20131955 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1388_CR342","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-21-2035","volume":"81","author":"EC Erickson","year":"2021","unstructured":"Erickson, E. C. & Toker, A. Can improved use of biomarkers alter the fate of PI3K pathway inhibitors in the clinic? Cancer Res. 81, 6083\u20136086 (2021).","journal-title":"Cancer Res."},{"key":"1388_CR343","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","volume":"177","author":"DT Patton","year":"2006","unstructured":"Patton, D. T. et al. Cutting edge: the phosphoinositide 3-kinase p110\u03b4 is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6598\u20136602 (2006).","journal-title":"J. Immunol."},{"key":"1388_CR344","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao, V. K. et al. Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib. Blood 130, 2307\u20132316 (2017).","journal-title":"Blood"},{"key":"1388_CR345","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.4049\/jimmunol.1103302","volume":"188","author":"TT Zhang","year":"2012","unstructured":"Zhang, T. T., Makondo, K. J. & Marshall, A. J. p110\u03b4 phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression. J. Immunol. 188, 3700\u20133708 (2012).","journal-title":"J. Immunol."},{"key":"1388_CR346","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007002","volume":"11","author":"V Mehra","year":"2023","unstructured":"Mehra, V. et al. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. J. Immunother. Cancer 11, e007002 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1388_CR347","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","volume":"8","author":"JS Bowers","year":"2017","unstructured":"Bowers, J. S. et al. PI3K\u03b4 inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells. Front. Immunol. 8, 1221 (2017).","journal-title":"Front. Immunol."},{"key":"1388_CR348","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1073\/pnas.0405454101","volume":"101","author":"M Aoki","year":"2004","unstructured":"Aoki, M., Jiang, H. & Vogt, P. K. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc. Natl Acad. Sci. USA 101, 13613\u201313617 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1388_CR349","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ni.1689","volume":"10","author":"YM Kerdiles","year":"2009","unstructured":"Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176\u2013184 (2009).","journal-title":"Nat. Immunol."},{"key":"1388_CR350","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708908","volume":"12","author":"KH Johansen","year":"2021","unstructured":"Johansen, K. H., Golec, D. P., Thomsen, J. H., Schwartzberg, P. L. & Okkenhaug, K. PI3K in T cell adhesion and trafficking. Front. Immunol. 12, 708908 (2021).","journal-title":"Front. Immunol."},{"key":"1388_CR351","doi-asserted-by":"publisher","first-page":"14853","DOI":"10.1074\/jbc.273.24.14853","volume":"273","author":"W Nagel","year":"1998","unstructured":"Nagel, W. et al. Phosphoinositide 3-OH kinase activates the \u03b22 integrin adhesion pathway and induces membrane recruitment of cytohesin-1. J. Biol. Chem. 273, 14853\u201314861 (1998).","journal-title":"J. Biol. Chem."},{"key":"1388_CR352","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1128\/MCB.02011-06","volume":"27","author":"G Menasche","year":"2007","unstructured":"Menasche, G. et al. RIAM links the ADAP\/SKAP-55 signaling module to Rap1, facilitating T-cell-receptor-mediated integrin activation. Mol. Cell. Biol. 27, 4070\u20134081 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"1388_CR353","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abl9169","volume":"15","author":"KH Johansen","year":"2022","unstructured":"Johansen, K. H. et al. A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1-mediated adhesion in T cells. Sci. Signal. 15, eabl9169 (2022).","journal-title":"Sci. Signal."},{"key":"1388_CR354","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ni.1884","volume":"11","author":"W Ouyang","year":"2010","unstructured":"Ouyang, W. et al. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 11, 618\u2013627 (2010).","journal-title":"Nat. Immunol."},{"key":"1388_CR355","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1084\/jem.20100004","volume":"207","author":"Y Harada","year":"2010","unstructured":"Harada, Y. et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J. Exp. Med. 207, 1381\u20131391 (2010).","journal-title":"J. Exp. Med."},{"key":"1388_CR356","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.20071477","volume":"205","author":"S Haxhinasto","year":"2008","unstructured":"Haxhinasto, S., Mathis, D. & Benoist, C. The AKT\u2013mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565\u2013574 (2008).","journal-title":"J. Exp. Med."},{"key":"1388_CR357","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fimmu.2012.00244","volume":"3","author":"DR Soond","year":"2012","unstructured":"Soond, D. R., Slack, E. C., Garden, O. A., Patton, D. T. & Okkenhaug, K. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front. Immunol. 3, 244 (2012).","journal-title":"Front. Immunol."},{"key":"1388_CR358","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017359","volume":"6","author":"DT Patton","year":"2011","unstructured":"Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R. & Okkenhaug, K. The PI3K p110\u03b4 regulates expression of CD38 on regulatory T cells. PLoS One 6, e17359 (2011).","journal-title":"PLoS One"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01388-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:04:19Z","timestamp":1780661059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":358,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01388-5","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"29 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.V. is a consultant for iOnctura (Geneva, Switzerland); a shareholder of Open Orphan and Poolbeg Pharma (Dublin, Ireland); and a director of S&B Scientific. J.R.B. has served as a consultant for Abbvie, Acerta\/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Bristol-Myers Squibb, EcoR1, Galapagos NV, Genentech\/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, Loxo\/Lilly, Magnet Biomedicine, Merck and Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo\/Lilly, MEI Pharma, Nagoon Therapeutics and TG Therapeutics; and serves on the Data Safety Monitoring Board for Grifols Therapeutics. N.V. reports consultin\n                      g\n                      for Apertor Therapeutics, Avenzo Therapeutics, GLG, Guidepoint Global, Reactive Biosciences and Scorpion Therapeutics; royalties from Wolters Kluwer; and stock in Reactive Biosciences, Heligenics, Inc. M.W.D.P. is an employee of and stockholder in AstraZeneca. S.E.C. has no interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}